Todd Liao

Dec 23, 2024 | jdsupra.com | Todd Liao

As of November 1, 2024, China has officially implemented the beneficiary owner information (BOI) filing requirements for all business entities in the country following the effectiveness of the Administrative Measures on Beneficial Owner Information (受益所有人信息管理办法, or the Measures). The Measures were jointly issued by the People’s Bank of China (PBOC) and the State Administration for Market Regulation (SAMR) in April 2024.

Oct 23, 2024 | jdsupra.com | Bingna Guo |Todd Liao |K Lesli Ligorner

The China State Administration for Market Regulation (SAMR) recently released the draft of the Compliance Guide for Healthcare Companies to Prevent Commercial Bribery (Draft Guide). The Draft Guide, issued amid China’s intensifying anti-corruption campaign targeting the healthcare sector, comes in a year that has seen record enforcement actions and investigations.

Oct 22, 2024 | morganlewis.com | Todd Liao |K Lesli Ligorner |Bingna Guo

The China State Administration for Market Regulation (SAMR) recently released the draft of the Compliance Guide for Healthcare Companies to Prevent Commercial Bribery (Draft Guide). The Draft Guide, issued amid China’s intensifying anti-corruption campaign targeting the healthcare sector, comes in a year that has seen record enforcement actions and investigations.

Oct 22, 2024 | lexology.com | Todd Liao |K Lesli Ligorner |Bingna Guo

The China State Administration for Market Regulation (SAMR) recently released the draft of the Compliance Guide for Healthcare Companies to Prevent Commercial Bribery (Draft Guide). The Draft Guide, issued amid China’s intensifying anti-corruption campaign targeting the healthcare sector, comes in a year that has seen record enforcement actions and investigations.

Oct 14, 2024 | lexology.com | Todd Liao |Fan Shi

The Shanghai Health Commission, together with 13 other governmental authorities in Shanghai, jointly published on October 10, 2024 the Shanghai version of the 2024 Notice on Issuing the Key Points of Correcting Improper Practices in Pharmaceutical Purchase and Sales as well as Medical Services in 2024 (2024 Notice). This 2024 Notice aligns substantially with the national annual framework guidelines issued by 14 national-level authorities in May.